trelstar and Overweight

The prevalence of precocious puberty is increasing. Obesity has been demonstrated to be associated with changes in the adipokine profile and incidence of early puberty in girls. This study assessed the pubertal signs, the levels of adiponectin, resistin, and tumor necrosis factor-alpha (TNF-α) after 12 weeks of combined exercise and 4 weeks of detraining in overweight and obese girls with precocious puberty.. Thirty overweight and obese girls (aged 7-9) with precocious puberty, who had received Triptorelin, were randomly divided into two groups (15 exercise and 15 control). Initially, serum levels of adiponectin, resistin, TNF-α, luteinising hormone (LH), and follicle-stimulating hormone (FSH) and the signs of puberty progression (bone age, uterine length, and ovarian volume) were measured. The exercise group performed 60 min of combined (aerobic and resistance) exercise three times/week for 12 weeks. The control group did not receive any exercise. 48 h after the last training session and after 4 weeks of detraining, all research variables were measured (also in the control group). The statistical method used for data analysis was repeated measures ANOVA.. In the exercise group, adiponectin significantly increased and resistin significantly decreased after 12 weeks. After 4 weeks of detraining, adiponectin significantly decreased, but resistin significantly increased. TNF-α levels did not change significantly during the study. There was no significant difference in all of the factors in the control group. Throughout the 16-week study period, the rate of puberty and LH significantly decreased in both exercise and control groups, but FSH, LH/FSH and ovarian volume significantly decreased in the exercise group alone (P<0.05).. Combined exercise increased adiponectin and decreased resistin and the rate of puberty. However, after 4 weeks of detraining, these effects diminished but did not disappear.. IRCT, IRCT56471. Registered 25 may 2021 - Retrospectively registered, https://fa.irct.ir/user/profile.

Topics: Adipokines; Adiponectin; Child; Exercise; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Overweight; Pediatric Obesity; Puberty, Precocious; Resistin; Treatment Outcome; Triptorelin Pamoate; Tumor Necrosis Factor-alpha

In an attempt to evaluate the effectiveness of a novel modified ultra-long agonist (ULA) protocol on polycystic ovary syndrome (PCOS) patients undergoing in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI), a retrospective study of 499 women employed with either ULA or conventional long agonist (LA) protocol was analyzed. In high BMI group (>25 kg/m²), the ULA protocol yielded significant higher clinic pregnancy rate (PR) (70.2% versus 50.8%, p < 0.05), implantation rate (52.7% versus 35.7%, p < 0.05) and live birth rate (63.8% versus 39.0%, p < 0.05) when compared with LA protocol. In low BMI group (≤25 kg/m²), the ULA protocol also demonstrated a higher clinic PR (70.8% versus 59.5%, p < 0.05) whereas implantation rate and live birth rate are comparable. Within ULA protocol, the clinic PR, implantation rate and live birth rate are similar between high and low BMI patients. Similarly, the clinic PR and live birth rate demonstrated no significant difference within LA group but there is a significant lower implantation rate (35.7% versus 63.9%, p < 0.05) observed in high BMI patients. No difference in miscarriage rate and severe OHSS rate was found among all groups. In conclusion, ULA protocol benefits the IVF outcomes of PCOS patients with high BMI status.

Topics: Adult; Birth Rate; Body Mass Index; China; Drug Administration Schedule; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Infertility, Female; Luteolytic Agents; Ovarian Hyperstimulation Syndrome; Overweight; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Maintenance; Pregnancy Rate; Retrospective Studies; Sperm Injections, Intracytoplasmic; Triptorelin Pamoate

In modern society, obesity has become a major health problem and has been associated with impaired fertility. The aim of this study is to assess the role of obesity in women undergoing controlled ovarian hyperstimulation (COH) stimulated either with GnRH agonists or with GnRH antagonists. Records of 463 women undergoing in vitro fertilization (IVF) treatment were reviewed. The influence of body mass index (BMI) on treatment outcome was examined, after accounting for differences in stimulation protocols. In the agonist group (286 patients), the total amount of gonadotropins used was significantly higher in patients with a BMI ≥ 25 kg/m², when compared to those with a normal BMI. The same result was found in the antagonist group (177 patients). No significant differences were found in length of stimulation, number of oocytes retrieved or number of embryos transferred. In both the antagonist and the agonist group, the number of clinical pregnancies was found to be higher in patients with normal BMI, suggesting that obesity could impair the ovarian response to exogenous gonadotropins. Considering the results obtained and the many theoretical advantages of GnRH antagonists, ovarian stimulation with GnRH antagonists is an efficient treatment for both women with normal and high BMI.

Topics: Adult; Body Mass Index; Dose-Response Relationship, Drug; Embryo Transfer; Female; Fertilization in Vitro; Follicle Stimulating Hormone, Human; Gonadotropin-Releasing Hormone; Gonadotropins; Hormone Antagonists; Humans; Infertility, Female; Obesity; Ovary; Overweight; Ovulation Induction; Pregnancy; Prospective Studies; Recombinant Proteins; Triptorelin Pamoate; Ultrasonography

We studied the effect of gonadotropin-releasing hormone analogues (GnRHa) on weight gain as a possible side effect.. We analyzed longitudinally changes in BMI-SDS in 92 children [median age 8.0 years (IQR 7.1-8.9), 88% females, mean BMI-SDS 0.69 ± 1.30] with idiopathic central precocious puberty or early puberty treated with GnRHa. Furthermore, 25 overweight children with GnRHa were compared to 25 overweight children without GnRHa matched by age, gender, degree of overweight, and pubertal stage.. The matched overweight children without GnRHa demonstrated a significant increase in their BMI-SDS in the course of 1 year (+0.18 ± 0.22). Normal-weight children treated with GnRHa demonstrated a significant increase in BMI-SDS in the course of 1 year (+0.32 ± 0.66) in contrast to overweight children treated with GnRHa who showed a stable BMI-SDS (-0.02 ± 0.27). This significant difference in changes in BMI-SDS between normal-weight and overweight children treated with GnRHa was also observed at the end of GnRHa treatment and 6 months later (p < 0.001).. Change in weight status differed between overweight and normal-weight children during GnRHa treatment. We found no increased risk for the side effect of weight gain in overweight children treated with GnRHa.

Topics: Body Height; Body Mass Index; Body Weight; Child; Female; Gonadotropin-Releasing Hormone; Humans; Longitudinal Studies; Male; Overweight; Puberty, Precocious; Retrospective Studies; Triptorelin Pamoate; Weight Gain

To explore the effects of overweight and obesity on the outcomes of in vitro fertilisation (IVF) in Chinese infertile patients.. A retrospective cohort study was carried out in 2222 normal weight (18.5 or= 30) women who underwent their first IVF cycles between 2002 and 2008. Cycle characteristics and IVF outcomes were analysed.. Obese women required significantly higher dose of rFSH (3272 IU vs. 2587 IU, p < 0.001) and days of stimulation (11.89 +/- 4.57 vs. 10.42 +/- 2.03, p < 0.001), but exhibited less oocytes retrieved and significantly lower fertilisation rate (54.1% vs. 61.1%, p < 0.001) than normal weight women. Compared with normal weight women, overweight women displayed significantly less oocytes retrieved (12.98 +/- 6.91 vs. 14.49 +/- 7.96, p < 0.001), lower fertilisation rate (60.8 +/- 23.3 vs. 61.1 +/- 23.0, p < 0.001), less cleavaged embryos (7.55 +/- 4.86 vs. 8.67 +/- 5.90, p < 0.001), less high-grade embryos (4.65 +/- 3.96 vs. 5.59 +/- 4.81, p < 0.001) and cryopreserved embryos (4.44 +/- 4.55 vs. 5.49 +/- 5.55, p < 0.001). All parameters of pregnancy outcomes, including pregnancy rate, miscarriage rate and live birth rate, were comparable among three groups.. Overweight and obesity are related with impared ovarian response, and negatively affect the outcomes of IVF.

Topics: Adult; Body Mass Index; China; Cohort Studies; Cryopreservation; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Infertility; Obesity; Oocytes; Overweight; Ovulation Induction; Pregnancy; Pregnancy Outcome; Recombinant Proteins; Retrospective Studies; Sperm Injections, Intracytoplasmic; Tissue and Organ Harvesting; Treatment Outcome; Triptorelin Pamoate

Was to evaluate the body mass index (BMI) changes in girls with central precocious puberty (CPP) treated with a GnRH analog (GnRHa) and to analyse the factors affecting BMI.. 43 girls with puberty onset aged (mean, +/-SD) 6.1+/-1.9, treated with 3.75 mg Decapeptyl Depot i.m. every 28 days. The treatment was initiated at the age of 7.5+/-2.1 year and continued for 3.3+/-2.2 year until the age of 11.4+/-0.9 year. The height, weight and BMI data were evaluated before, during and after GnRH agonist administration. Using recommended Polish BMI cut-off values we defined overweight in children of 90th and 97th centiles and obesity above 97th centile.. There was no statistical difference between BMI SD score before initiation of therapy and at the end of therapy (p=0.49). 9.8% of the cohort were overweight and 22.0% were obese before treatment. At the end of the therapy 18.6% children were overweight and 14.0% obese. These differences were not statistically significant. There was no significant correlation between overweight and obesity at the end of treatment and the duration of the therapy (r=-0.17) and with the duration of CPP before introduction of GnRH therapy (r= -0.11).. 1.Overweight and obesity are not related to long term pituitary-gonadal suppression due to GnRH analogue treatment. 2. The rate of overweight and obesity among children with CPP is higher than in the general population. Thus detailed evaluation of metabolic status of overweight children with CPP should be performed in order to prevent complications of the metabolic syndrome.

Topics: Body Height; Body Mass Index; Child; Cohort Studies; Comorbidity; Female; Humans; Obesity; Overweight; Prevalence; Puberty, Precocious; Triptorelin Pamoate